Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,912 | $1,604 | $1,519 | $1,296 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Cost of Goods Sold | $349 | $292 | $288 | $253 |
| Gross Profit | $1,563 | $1,311 | $1,230 | $1,043 |
| % Margin | 81.7% | 81.8% | 81% | 80.5% |
| R&D Expenses | $328 | $294 | $276 | $246 |
| G&A Expenses | $843 | $740 | $630 | $549 |
| SG&A Expenses | $843 | $740 | $630 | $549 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $351 | $251 | $38 | $28 |
| Operating Expenses | $1,522 | $1,286 | $945 | $823 |
| Operating Income | $41 | $26 | $133 | $220 |
| % Margin | 2.1% | 1.6% | 8.8% | 17% |
| Other Income/Exp. Net | -$10 | -$1 | -$1 | -$63 |
| Pre-Tax Income | $31 | $25 | $132 | $157 |
| Tax Expense | -$20 | $8 | $34 | $33 |
| Net Income | $51 | $17 | $99 | $124 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS | 28.35 | 9.5 | 54.24 | 67.08 |
| % Growth | 198.4% | -82.5% | -19.1% | – |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $11 | $8 | $6 |
| Interest Expense | $18 | $12 | $9 | $5 |
| Depreciation & Amortization | $199 | $158 | $106 | $80 |
| EBITDA | $248 | $195 | $337 | $298 |
| % Margin | 13% | 12.1% | 22.2% | 23% |